Intra-articular GHK-Cu injections transiently improved graft healing and stiffness in a rat ACL reconstruction model
Background
Following anterior cruciate ligament reconstruction (ACLR), the biological healing of the graft is a critical, rate-limiting step that often determines the long-term success of the surgery. Poor or slow healing can contribute to graft laxity and eventual failure, a significant clinical problem. Current surgical techniques focus on mechanical stability but have limited options to accelerate the biological integration and remodeling of the tendon graft. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(II) (GHK-Cu) is a known activator of tissue remodeling processes. This study investigates whether local administration of GHK-Cu could enhance graft healing, potentially offering a new pharmacological adjunct to improve ACLR outcomes.
Study Design
Seventy-two rats underwent unilateral ACLR and were randomized into three groups (n=24 each): a saline control, a low-dose GHK-Cu group (0.3 mg/ml), and a high-dose GHK-Cu group (3 mg/ml). Starting at week 2 post-operation, they received intra-articular injections once a week for four consecutive weeks. Researchers performed gait analysis pre-injury and at the time of harvest. At 6 and 12 weeks post-operation, knee specimens were harvested to measure knee laxity, perform a graft pull-out test to assess mechanical properties, and conduct histological analysis.
Results
At 6 weeks post-ACLR, the GHK-Cu groups showed a significantly smaller side-to-side difference in knee laxity compared to the saline group (p=0.009). However, this improvement was not sustained, as no significant difference was observed at the 12-week mark. The graft complex in the 0.3 mg/ml GHK-Cu group also demonstrated higher stiffness than the saline group at 6 weeks (p=0.026).
Despite these early mechanical improvements, there were no significant differences in ultimate load at failure, gait parameters, or histological scores among any of the treatment groups at either time point. All grafts failed at the mid-substance during the mechanical pull-out tests, indicating the failure point was within the graft tissue itself rather than at the bone-tendon interface. The beneficial effects observed at 6 weeks did not persist after the treatment was discontinued at week 5.
Key Findings
- At 6 weeks, GHK-Cu groups had significantly less knee laxity vs. saline (p=0.009).
- At 6 weeks, the 0.3 mg/ml GHK-Cu group showed higher graft stiffness than saline (p=0.026).
- No significant differences in knee laxity were found between groups at 12 weeks post-operation.
- There were no significant differences in ultimate load, gait parameters, or histology scores among groups.
- The beneficial effects on healing were transient and did not last after treatment discontinuation.
Why It Matters
The findings suggest that local GHK-Cu administration could offer a temporary boost to graft healing in the early stages following ACL surgery, potentially improving initial stability. For biohackers or clinicians exploring peptides for injury recovery, this indicates a possible role for GHK-Cu in the immediate post-operative period. However, the transient nature of the effect is a crucial takeaway: sustained improvement may require a longer or different administration protocol, as the benefits disappeared once treatment stopped. This study highlights that while GHK-Cu can positively influence tissue mechanics, its application for something as complex as ligament graft healing is not straightforward. Further research is needed to determine optimal dosing, frequency, and duration to achieve lasting benefits before this could be considered a viable human protocol.
TitrateLab articles covering GHK-Cu
Written by TitrateLab, separately from the study summarized above.
ghk-cu
acl reconstruction
ligament healing
tendon graft
tissue remodeling
animal study
